Tuesday, May 06, 2014 9:31:07 AM
STEM - $1.25 - Upcoming Catalyst on 5/14/14 (or as always - may come before), according to Biopharmcatalyst.com.
--------------
NEWARK, CA, April 17, 2014 (GLOBE NEWSWIRE) — StemCells, Inc. (Nasdaq:STEM) announced today that it has completed enrollment in the Company’s Phase I/II clinical trial in spinal cord injury. The multi-national, open-label, Phase I/II trial is evaluating both safety and preliminary efficacy of StemCells, Inc.’s proprietary HuCNS-SC® human neural stem cells as a treatment for chronic spinal cord injury. The trial enrolled twelve subjects with chest-level injury to the spinal cord. The trial enrolled seven patients with complete paralysis, no motor or sensory function below the point of injury, classified as complete (AIS A), according to the American Spinal Injury Association Impairment Scale, and five patients with no motor function and limited sensory function below the point of injury classified as incomplete (AIS B). Zurich study site principal investigator, Dr. Armin Curt, will present an interim update based on six month data for the first six subjects at the American Spinal Injury Association conference this coming May. Final results from this landmark study are expected to be released mid-2015.
-------------------------
I've played STEM once before successfully as one of my first trades in December. I'm in agreement here with Smurf that it looks to be a good play in this area. Good support around $1.19 below. Full STO just curved up, MACD crossed recently, now need to get it up over 0, and RSI has sloped down, now is flattening out and possibly moving above 50.
Can wait it out and see if it moves down to $1.19 ish and snag a few shares, or buy now for a possible move up into the partial data release.
--------------
NEWARK, CA, April 17, 2014 (GLOBE NEWSWIRE) — StemCells, Inc. (Nasdaq:STEM) announced today that it has completed enrollment in the Company’s Phase I/II clinical trial in spinal cord injury. The multi-national, open-label, Phase I/II trial is evaluating both safety and preliminary efficacy of StemCells, Inc.’s proprietary HuCNS-SC® human neural stem cells as a treatment for chronic spinal cord injury. The trial enrolled twelve subjects with chest-level injury to the spinal cord. The trial enrolled seven patients with complete paralysis, no motor or sensory function below the point of injury, classified as complete (AIS A), according to the American Spinal Injury Association Impairment Scale, and five patients with no motor function and limited sensory function below the point of injury classified as incomplete (AIS B). Zurich study site principal investigator, Dr. Armin Curt, will present an interim update based on six month data for the first six subjects at the American Spinal Injury Association conference this coming May. Final results from this landmark study are expected to be released mid-2015.
-------------------------
I've played STEM once before successfully as one of my first trades in December. I'm in agreement here with Smurf that it looks to be a good play in this area. Good support around $1.19 below. Full STO just curved up, MACD crossed recently, now need to get it up over 0, and RSI has sloped down, now is flattening out and possibly moving above 50.
Can wait it out and see if it moves down to $1.19 ish and snag a few shares, or buy now for a possible move up into the partial data release.
These thoughts are just mine, not right, not wrong, just thoughts. Invest in what you believe in, not what I believe in. Do your research, and invest in the facts.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
